References
- World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. Geneva 27, Switzerland, 2007. https://apps.who.int/iris/handle/10665/43510
- Council of Europe (COE) – European Directorate for the Quality of Medicines. European Pharmacopoeia 6th Edition. Strasburg, 2007.
- British Pharmacopoeia Commission. British pharmacopoeia 2011. London: Stationery Office, 2011.
- United States Pharmacopeial Convention. Council of Experts. The United States pharmacopeia: the national formulary. 31st revision, Washington, 2008.
- Turcasso NM, Cooper JC. Herbal Medicine: Reliable Information Resources. Journal of Pharmacy Practice. 1999; 12(3): 187-195. https://doi.org/10.1177/089719009901200306
- Nathan M, Robert S. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Ann Intern Med. 1999; 130(5): 459 https://doi.org/10.7326/0003-4819-130-5-199903020-00024
- Ahmed E, Arshad M, Khan MZ et al. Secondary metabolites and their multidimensional prospective in plant life. Journal of Pharmacognosy and Phytochemistry. 2017; 6(2): 205-214.
- European Medicines Agency, „www.emea.europa.eu,“ 11 January 2007. [Online]. Available: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedure-preparation-community-monographs-traditional-herbal-medicinal-products_en.pdf. [Accessed 2022].
- Valchanova V, Petkova VB, Pharmacovigillance and cosmetovigilance to the European legislatio. Science Pharmacology. 2014; 2: 4-8.
- Kilova K, Mihaylova A, Peikova L. Opportunities of information communication technologies for providing pharmaceutical care in the COVID-19 pandemic. Pharmacia. 2021; 68(1): 9-14. https://doi.org/10.3897/pharmacia.68.e56987